This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Pain is arguably the most common symptom bringing patients to physicians. Neurologists need to be particularly attuned to the nuances of pain symptoms in order to determine whether the pain is due to primary involvement of the nervous system or is a nociceptive or somatic pain that is secondarily transmitted through pain pathways. As our knowledge of the pathophysiology of neuropathic pain becomes more sophisticated, and new treatments are developed, our ability to distinguish different types of neuropathic pain must become more sensitive. Equally important will be our ability to understand the common features of neuropathic pain. Does a treatment found to be effective for pain in diabetic neuropathy or postherpetic neuralgia have an equal likelihood of being therapeutic for neuropathic pain from other peripheral or CNS disorders? The Food and Drug Administration approval of pregabalin and duloxetine for diabetic neuropathic pain and postherpetic neuralgia but the off labeling for otherwise identical neuropathic pain from other causes highlights the importance of answering these questions.
In that context, in this issue of Neurology® the article by Treede et al.1 is most welcome. It is a consensus report of scientists and clinicians with interest and expertise in peripheral neuropathy …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
